5-chloromethyl-4-isopropyl-2-[4-(trifluoromethyl)phenyl]thiazole | 726174-61-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-chloromethyl-4-isopropyl-2-[4-(trifluoromethyl)phenyl]thiazole
• 英文别名: 5-(chloromethyl)-4-propan-2-yl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole
• CAS: 726174-61-4
• 化学式: C₁₄H₁₃ClF₃NS
• 分子量: 319.778
• InChiKey: ORLUWEFVZQWBGD-UHFFFAOYSA-N

物化性质

• 沸点：
  369.5±52.0 °C(Predicted)
• 密度：
  1.285±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-chloromethyl-4-isopropyl-2-[4-(trifluoromethyl)phenyl]thiazole 在 盐酸 、 水 、 溶剂黄146 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 24.92h， 生成 6-amino-3-[2-[4-isopropyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazole
  参考文献：
  名称：

  Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists

  摘要：

  We discovered novel peroxisome proliferator-activated receptor delta agonists with a characteristic benzisoxazole ring. Compound 5 exhibited potent human PPAR delta transactivation activity. Furthermore, it stimulated the differentiation of oligodendrocyte precursor cells in vitro. This indicates that this potential drug may be effective for the treatment of demyelinating disorders such as multiple sclerosis. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.03.053
• 作为产物：
  描述：

  4-(三氟甲基)硫代苯甲酰胺 在 氯化亚砜 、 磺酰氯 、 红铝 作用下， 以 甲苯 、 苯 为溶剂， 反应 25.75h， 生成 5-chloromethyl-4-isopropyl-2-[4-(trifluoromethyl)phenyl]thiazole
  参考文献：
  名称：

  Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists

  摘要：

  We discovered novel peroxisome proliferator-activated receptor delta agonists with a characteristic benzisoxazole ring. Compound 5 exhibited potent human PPAR delta transactivation activity. Furthermore, it stimulated the differentiation of oligodendrocyte precursor cells in vitro. This indicates that this potential drug may be effective for the treatment of demyelinating disorders such as multiple sclerosis. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.03.053

文献信息

• Indole derivatives as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060166983A1

  公开（公告）日：2006-07-27

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in (I) are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过使用结构式(I)的化合物调节过氧化物酶体增殖物激活受体进行治疗的方法。式(I)中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为对治疗和预防X综合症、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉粥样硬化以及其他与X综合症和心血管疾病有关的疾病有效。
• Peroxisome proliferator activated receptor modulators
  申请人：Conner Eugene Scott

  公开号：US20060084663A1

  公开（公告）日：2006-04-20

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: wherein: (a) R5 is selected from the group consisting of (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, substituted aryl(C 0 -C 4 )alkyl, substituted aryloxy(C 0 -C 4 )alkyl, substituted arylthio(C 0 -C 4 )alkyl, unsubstituted aryl(C 0 -C 4 )alkyl, unsubstituted aryloxy(C 0 -C 4 )alkyl, and unsubstituted arylthio(C 0 -C 4 )alkyl; (b) T1 is C or N; (c) Q is selected from the group consisting of O, a single bond, O(CH 2 ) q and C; (d) q is 1 or 2; (e) W is selected from the group consisting of O, S, (CH 2 ) r N(R20)(CH 2 ) k , NHSO 2 , C(O)N(R20)(CH 2 ) r , (CH 2 ) r N(R20)C(O), and SO 2 ; (f) X is C m H 2m ; (g) m is 0, 1 or 2; (h) A is an functional group selected from the group consisting of carboxyl, C1-C3 alkylnitrile, carboxamide, and (CH 2 ) n COOR19; and (i) R19 is selected from the group consisting of hydrogen, optionally substituted C1-C4alkyl and optionally substituted arylmethyl.

  本发明涉及以下结构式所表示的化合物及其药学上可接受的盐，式I：其中：(a) R5选自(C1-C6)烷基，(C1-C6)烯基，取代芳基(C0-C4)烷基，取代芳氧基(C0-C4)烷基，取代芳硫基(C0-C4)烷基，未取代芳基(C0-C4)烷基，未取代芳氧基(C0-C4)烷基和未取代芳硫基(C0-C4)烷基组成的群体；(b) T1为C或N；(c) Q选自O，单键，O(CH2)q和C的群体；(d) q为1或2；(e) W选自O，S，(CH2)rN(R20)(CH2)k，NHSO2，C(O)N(R20)(CH2)r，(CH2)rN(R20)C(O)和SO2的群体；(f) X为CmH2m；(g) m为0，1或2；(h) A为从羧基，C1-C3烷基腈，羧酰胺和(CH2)nCOOR19的群体中选取的一个功能基团；(i) R19选自氢，可选取代的C1-C4烷基和可选取代的芳基甲基的群体。
• Fused heterocyclic derivates as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060217374A1

  公开（公告）日：2006-09-28

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过利用结构式（I）的化合物来调节过氧化物酶体增殖物激活受体进行治疗的方法。I中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为在治疗和预防综合征X、H型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉粥样硬化和其他与综合征X和心血管疾病相关的疾病方面具有疗效。
• Fused heterocyclic derivatives as PPAR modulators
  申请人：Eli Lilly and Company

  公开号：US07528160B2

  公开（公告）日：2009-05-05

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过使用结构式（I）化合物调节过氧化物酶体增殖激活受体进行治疗的方法。I中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为对治疗和预防综合征X、H型糖尿病、高血糖、高脂血症、肥胖症、凝血异常、高血压、动脉粥样硬化和与综合征X和心血管疾病相关的其他疾病有效。
• Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases
  申请人：Barbaras Ronald

  公开号：US20110092517A1

  公开（公告）日：2011-04-21

  Provided herein are methods for treatment, prevention, or amelioration of one or more symptoms of a disease or condition related to disorders of insulin and/or glucose metabolism, inflammatory conditions, mitochondrial disease, muscle disorders, or pulmonary disorders, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist. In one embodiment, the disease or condition is selected from myopathy, inflammatory vascular diseases, Parkinson's and Alzheimer's diseases, systemic inflammatory disorders, renal ischemia, inflammatory rheumatic disorders, and inflammatory diseases of the lung. In another embodiment, methods for increasing oxidative muscle fibers, reducing mitochondria disease, decreasing insulin resistance, decreasing plasma glucose, or decreasing weight, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist, are provided.

  本文提供了治疗、预防或改善与胰岛素和/或葡萄糖代谢紊乱、炎症性疾病、线粒体病、肌肉疾病或肺部疾病相关的一种或多种症状的方法，其中涉及给予一种PPARδ激动剂或含有PPARδ激动剂的制剂。在一种实施例中，所述疾病或症状被选自肌无力、炎症性血管疾病、帕金森和阿尔茨海默病、全身性炎症性疾病、肾脏缺血、炎症性风湿病和肺部炎症性疾病。在另一种实施例中，提供了通过给予PPARδ激动剂或含有PPARδ激动剂的制剂来增加氧化肌纤维、减少线粒体疾病、降低胰岛素抵抗、降低血浆葡萄糖或减轻体重的方法。